SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated with Gemcitabine, S-1, or Gemcitabine plus S-1

GEST

Research output: Contribution to journal › Article › peer-review

3 Citations (Scopus)

Fingerprint

Dive into the research topics of 'SLCO1B1 Polymorphism Is a Drug Response Predictive Marker for Advanced Pancreatic Cancer Patients Treated with Gemcitabine, S-1, or Gemcitabine plus S-1'. Together they form a unique fingerprint.

Medicine & Life Sciences